Mesh Reinforcement of Pancreatic Transection Decreases Incidence of Pancreatic Occlusion Failure for Left Pancreatectomy: a Single-blinded, Randomized Controlled Trial
Overview
Authors
Affiliations
Introduction: Pancreatic leak or fistula is the most frequent complication after left pancreatectomy. We performed a single-blinded, parallel-group, randomized controlled trial comparing stapled left pancreatectomy with stapled left pancreatectomy using mesh reinforcement of the staple line with either Seamguard or Peristrips Dry.
Methods: All patients undergoing left pancreatectomy at a large tertiary hospital were eligible for participation. Patients were randomized to either mesh reinforcement or no-mesh reinforcement intraoperatively after being determined a candidate for resection. Patients were blinded to the result of their randomization for 6 weeks. Primary outcome measure was clinically significant leak as defined by the ISGPF (International Study Group on Pancreatic Fistula) pancreatic leak grading system.
Results: One hundred patients were randomized to either mesh (54) or no-mesh (46) reinforcement of their pancreatic transection. There was 1 death in each group. ISGPF grade B and C leaks were seen in 1.9% (1/53) of patients undergoing resection with mesh reinforcement and 20% (11/45) of patients without mesh reinforcement (P = .0007).
Conclusions: Mesh reinforcement of pancreatic transection line significantly reduces the incidence of significant pancreatic fistula in patients undergoing left pancreatectomy.
Trial Registration: Clinicaltrials.gov: NCT01359410.
Interaction analysis of subgroup effects in randomized trials: the essential methodological points.
Fingerhut A, Uranues S, Dziri C, Ma J, Vernerey D, Kurihara H Sci Rep. 2024; 14(1):12619.
PMID: 38824173 PMC: 11144206. DOI: 10.1038/s41598-024-62896-1.
Hajibandeh S, Hajibandeh S, Hablus M, Bari H, Pathanki A, Ali M Ann Hepatobiliary Pancreat Surg. 2024; 28(3):302-314.
PMID: 38522846 PMC: 11341886. DOI: 10.14701/ahbps.24-015.
Surgical management of pancreatic ductal adenocarcinoma: a narrative review.
Sarfaty E, Khajoueinejad N, Zewde M, Yu A, Cohen N Transl Gastroenterol Hepatol. 2023; 8:39.
PMID: 38021357 PMC: 10643215. DOI: 10.21037/tgh-23-27.
Uranues S, Fingerhut A, Belyaev O, Zerbi A, Boggi U, Hoffmann M Ann Surg Open. 2023; 2(1):e033.
PMID: 37638240 PMC: 10455066. DOI: 10.1097/AS9.0000000000000033.
The clinical effectiveness of staple line reinforcement with different matrix used in surgery.
Jing W, Huang Y, Feng J, Li H, Yu X, Zhao B Front Bioeng Biotechnol. 2023; 11:1178619.
PMID: 37351469 PMC: 10282759. DOI: 10.3389/fbioe.2023.1178619.